Ingredient Engine · Demonstration 1
Curcumin's solubility problem, worked through four fixes
Curcumin, the main pigment of turmeric, barely dissolves in water and breaks down at intestinal pH. This demonstration compares four formulation strategies for it: what each one physically changes, how each fails, and which experiments would tell them apart. Better solubility is a laboratory result. Only a pharmacokinetic study shows exposure, and exposure is not benefit.
Educational demonstrationCompany in formation (what exists today). Published values are cited; hypothetical inputs are labeled; nothing here is a measured EUTECNIQ result or dosing advice.
How much water would dissolve a 500 mg dose? Liters of water at three published solubility values, log scale
In brief · The comparative verdict
No strategy wins on solubility alone: each fixes a different limit, and only a dose-matched human PK study can rank their exposure for a product
Curcumin's dose number stays far above 1, and no particle size changes that. The four strategies act on different quantities, carry different costs for curcumin, and have different amounts of published evidence behind them.
| Strategy | Changes | Main constraint for curcumin | Strongest curcumin evidence found | Deciding laboratory test |
|---|---|---|---|---|
| Lipid-based SNEDDS | Solubilized state (no dissolution step) | Capacity: about 24 g of preconcentrate for 500 mg at 21 mg/g | In vitro and animal for a self-microemulsifying system (Cui et al. 2009); no self-emulsifying human study found | In vitro lipolysis with phase separation and solid-form check |
| Cyclodextrin complex | Apparent solubility (equilibrium) | Mass: at least 3.1–3.5 g of cyclodextrin per g | Human PK: 39-fold higher total curcuminoid AUC for a γ-cyclodextrin formulation, 12 volunteers (Purpura et al. 2018) | Phase-solubility diagram and dilution test |
| Nanocrystal | Dissolution rate (surface area) | Dose number stays far above 1 | Rats: 16-fold for a nanocrystal solid dispersion (Onoue et al. 2010). In humans, a colloidal nanoparticle preparation of unstated solid form gave 27-fold (Sasaki et al. 2011) | Non-sink dissolution; size and form over storage |
| Amorphous solid dispersion | Supersaturation (kinetic) | Physical stability: crystallization inhibition was limited | Rats: 12-fold (Onoue et al. 2010); a human study is listed in a review, but its report was not reviewed | Two-stage supersaturation test; humidity stability |
Verdict: choose candidates from the families that act on the diagnosed limit, test them against preset stop rules, and rank them only with a crossover PK study against a dose-matched unformulated comparator. Fold-changes from different studies are not comparable. None of the four addresses metabolism or elimination, and all four leave dissolved curcumin exposed at intestinal pH.
Published evidence Hypothetical example Summarizes sections 04 (side by side) and 05 (evidence), with the stop rules of 06. The 500 mg dose is hypothetical. The equations behind the dose number follow in section 02.
01 · The molecule
Curcumin is lipophilic, crystalline and least stable where it dissolves best
Every property below is cited to its source. Where sources disagree, both values are shown, because the disagreement is itself a formulation fact: curcumin's solubility in water is hard to measure.
| Property | Published value | What it means for formulation | Source |
|---|---|---|---|
| Molecular weight | 368.4 g/mol (C21H20O6) | Sets the mass of carrier per mole of curcumin, for example in a 1:1 cyclodextrin complex | PubChem CID 969516 (computed) |
| Lipophilicity, log P | XLogP3 3.2 (computed); about 3.0 (review); calculated values 2.3–3.2 | A log P near 3 means about a thousandfold preference for octanol over water: lipid excipients can dissolve it where gut fluid cannot | PubChem; Priyadarsini 2014; Nelson et al. 2017 |
| Melting point | 183 °C (HSDB); 179–182 °C (EU food additive listing) | A stable crystal: the lattice must be broken (dissolved, milled or made amorphous) before curcumin is available | PubChem, from HSDB and EU Food Improvement Agents |
| Solubility in water | "Insoluble in water"; estimated 1–10 µg/mL at room temperature and neutral pH, "only an estimate" because curcumin aggregates; 11 ng/mL quoted for pH 5 buffer | Values differ by up to a thousandfold, so a formulation decision should not rest on one literature number; it should be measured in the intended medium | PubChem (HSDB); Nelson et al. 2017; Brotons-Canto et al. 2021, quoting earlier work |
| Acidity constants | pKa 8.38 ± 0.04, 9.88 ± 0.02 and 10.51 ± 0.01 in water (one study); a review reports ranges of 8.5–10.4 and 9.5–10.7 for the first two | Neutral below about pH 8, which covers the pH 1.2–6.8 range of ICH M9 solubility testing; the ionized form above it is more soluble and also degrades | Bernabé-Pineda et al. 2004; Nelson et al. 2017 |
| Stability against pH | About 90% decomposed within 30 min in pH 7.2 phosphate buffer at 37 °C; decomposition faster at neutral to basic pH across pH 3–10 | Dissolved curcumin can be lost to degradation before it is absorbed; a solubility measurement at intestinal pH can be confounded by breakdown | Wang et al. 1997 |
In an emulsion, curcumin kept best below pH 7 Curcumin retained after one month at 37 °C in oil-in-water emulsions, % (Kharat et al. 2017); dashed lines: acidity constants in water (Bernabé-Pineda et al. 2004)
Data table
| Storage pH | Retained, % |
|---|---|
| Below 7 (acidic conditions) | > 85 |
| 7.0 | 62 |
| 7.4 | 60 |
| 8.0 | 53 |
The barrier is therefore twofold: too little dissolves at gut pH, and what dissolves near neutral pH degrades. A strategy that raises solubility without protecting the molecule may only move the loss to a later step.
Notes and limits
Absorption is not curcumin's only obstacle. Anand and colleagues attributed its low plasma and tissue levels to "poor absorption, rapid metabolism, and rapid systemic elimination" (Mol Pharm. 2007). A solubility fix acts on the first of these and leaves the other two in place. Nelson and colleagues report that in one dose-escalation study curcumin was detected in the serum of only 2 of 6 people given single doses of 10 or 12 g.
The 11 ng/mL figure is widely quoted for pH 5 buffer; the measurement is usually attributed to Tønnesen, Másson and Loftsson (2002), whose full text was not reviewed. The abstract of that paper reports that cyclodextrin complexation raised curcumin's water solubility at pH 5 "by a factor of at least 104".
02 · The arithmetic
Smaller particles dissolve faster, but no particle size fixes the dose number
Two dimensionless numbers separate the problems. The dose number Do asks whether the fluid can hold the dose at all. The dissolution number Dn asks whether particles finish dissolving within small-intestinal transit, assuming the fluid never saturates.
Dose number and dissolution number for crystalline curcumin Hypothetical example
1 to 5,000 mg. 500 mg is the curcuminoid dose of one human study (Schiborr et al. 2014); not a recommendation.
Published values; see section 01.
Log scale, 0.1 to 100 µm. One size for all particles.
- Dose number Do
- 2,000
- Water to dissolve the dose
- 500L
- Dissolution number Dn
- 0.024
- Time for one particle to dissolve, sink
- 5.81days
Both dissolution rate and solubility limit this case. Particles of this size would not finish dissolving within transit even in unlimited fluid, and 250 mL could hold only about 0.05% of the dose.
Dissolution number against particle diameter Log–log; one line per published solubility; the hollow marker follows the calculator
Method, assumptions and limits
- What it calculates
- The dose number, the volume of water that would dissolve the dose, the dissolution number and the time for one particle to dissolve under sink conditions.
- Equations
- Do = (M0/V0)/Cs with V0 = 250 mL; volume = M0/Cs; Dn = 3D CsTsi/(r²ρ); dissolution time = Tsi/Dn = r²ρ/(3D Cs).
- Variables and units
- M0 dose, mg; Cs solubility, converted from µg/mL to mg/mL and g/cm³; r particle radius (half the diameter), cm; D = 5 × 10⁻⁶ cm²/s; ρ = 1.2 g/cm³; Tsi = 199 min.
- Assumptions
- Spherical particles of one size; sink conditions for Dn (the dissolved concentration stays far below Cs); no degradation, no micellar solubilization by bile, no supersaturation, no change of Cs with particle size.
- Valid range
- A screening estimate. When Do is far above 1 the sink assumption fails within minutes, so a large Dn then says the rate is not the limit; it does not say the dose dissolves. Real gut water volumes are smaller than 250 mL (see Bioavailability by design).
- What it does not establish
- Absorption, exposure or benefit of any product. The D and ρ values are generic defaults, not measured for curcumin.
- Verification
- An independent reference calculation reproduces every readout for the nine cases in the table below.
Amidon GL, et al. Pharm Res. 1995;12(3):413–420; Abuhassan Q, et al. Eur J Pharm Biopharm. 2022;170:160–169 (equation forms and default values); ICH M9 (2019), 250 mL. Noyes–Whitney background: Dokoumetzidis A, Macheras P. Int J Pharm. 2006;321:1–11.
Table: the nine reference cases (500 mg, hypothetical)
| Solubility | Do | Water for 500 mg | Dn at 50 µm | Dn at 5 µm | Dn at 0.25 µm |
|---|---|---|---|---|---|
| 11 ng/mL | 182,000 | 45,500 L | 0.00026 | 0.026 | 10.5 |
| 1 µg/mL | 2,000 | 500 L | 0.024 | 2.4 | 955 |
| 10 µg/mL | 200 | 50 L | 0.24 | 23.9 | 9,550 |
Milling curcumin to 0.25 µm moves Dn above 1 at every published solubility, while Do stays between 200 and 182,000. The limit is how much the fluid can hold. Strategies that keep curcumin dissolved in a carrier, or hold it above its crystalline solubility for a time, act on that limit; size reduction alone does not.
03 · Four strategies
Each strategy changes a different quantity, and each fails in its own way
Choose a strategy to see its mechanism, what it changes, its constraints, how it fails and the experiments that would confirm it. Each panel ends with the curcumin evidence by level; in vitro, animal and human pharmacokinetic (PK) results answer different questions, and section 05 sets them side by side.
Lipid-based self-nanoemulsifying system (SNEDDS): dissolve curcumin first, then keep it dissolved
What it changes: the form in which curcumin arrives. It is already dissolved in oil, surfactant and cosolvent, and stays dissolved only while droplets, and after digestion mixed micelles, can hold it. Its aqueous solubility is unchanged.
- Loading and excipient burden
- Capped by solubility in the preconcentrate. One self-microemulsifying system dissolved 21 mg of curcumin per gram (Cui et al. 2009); at that capacity a hypothetical 500 mg dose would need about 24 g of preconcentrate. That system was 57.5% surfactant, 30% PEG 400 and 12.5% oil.
- Dilution and digestion
- Surfactant- and cosolvent-rich systems can lose solvent capacity as they are diluted and digested. In standardized digestion tests, drugs crystallized from medium-chain and surfactant-only formulations only when the calculated maximum supersaturation ratio exceeded 3 (Williams et al. 2013, with fenofibrate and tolfenamic acid).
- Physical and chemical stability
- Curcumin in an emulsion still degraded at pH 7 and above (Kharat et al. 2017); the oil phase can oxidize; each excipient's status for a food or supplement must be checked separately from its use in medicines.
Typical failure modes: precipitation after dilution or digestion; a dose too large for the capsule volume; chemical loss of curcumin in the aqueous phase.
Confirmatory experiments: solubility in candidate oils, surfactants and cosolvents; dispersion at several dilutions with droplet size; in vitro lipolysis with curcumin measured in the aqueous phase and in the pellet, and X-ray powder diffraction of the pellet; stability-indicating HPLC; then a human PK study.
Curcumin evidence: in vitro and animal (rat in situ, mouse oral) for a self-microemulsifying system (Cui et al. 2009); no human study of a self-emulsifying system found. Details
Cyclodextrin inclusion complex: raise the apparent solubility through an equilibrium
What it changes: the apparent solubility, meaning free plus complexed curcumin. The complex is in dynamic equilibrium with free drug, and drug is "readily released from the complex upon media dilution or by competitive complexation" (Saokham et al. 2018). For curcumin, complexation raised water solubility at pH 5 by at least 104 and strongly improved hydrolytic stability under alkaline conditions, while photodecomposition was faster than in an organic-solvent solution (Tønnesen et al. 2002).
- Loading and excipient burden
- At least one cyclodextrin per curcumin in a 1:1 complex: 1,135 g/mol for β-cyclodextrin and 1,297 g/mol for γ-cyclodextrin against 368.4 g/mol for curcumin, or 3.1 and 3.5 g per g. A hypothetical 500 mg dose would carry at least 1.5 or 1.8 g of cyclodextrin before any excess. "The formulation bulk usually limits the amount of CD that can be included in solid dosage forms."
- Dilution and competition
- Dilution and competing molecules in the gut release the drug, which is the intended release route and also a precipitation risk if free curcumin exceeds its own solubility. Large cyclodextrin excess can hamper release.
- Physical stability
- Complexes of the natural cyclodextrins can self-assemble into aggregates and have limited solubility (Saokham et al. 2018). Because curcumin's intrinsic solubility is uncertain, the complexation efficiency (from the slope) is more reliable than the stability constant.
Typical failure modes: low complexation efficiency and a large serving; a physical mixture mistaken for a complex; photodegradation in the dissolved state.
Confirmatory experiments: phase-solubility diagram at the relevant pH; solid-state evidence that a complex formed rather than a physical mixture; dissolution and dilution testing; stability under light and at intestinal pH; then a human PK study.
Curcumin evidence: in vitro (Tønnesen et al. 2002) and human PK, 39-fold total curcuminoids for one γ-cyclodextrin formulation (Purpura et al. 2018). Details
Nanocrystal: raise the dissolution rate by raising surface area
What it changes: the dissolution rate, through surface area per gram. Below about 1 µm the saturation solubility also rises as size falls (the Ostwald–Freundlich relation, Li et al. 2021), but the particle remains crystalline and the fluid's capacity stays near the crystalline value. Section 02 shows the consequence for curcumin: Dn can exceed 1 while Do stays far above 1.
- Loading and excipient burden
- Low compared with carriers: the particle is the drug crystal, coated with a stabilizer. Drug nanocrystals "usually require the addition of stabilizers such as polymers or surfactants" (Li et al. 2021).
- Dilution and the gut
- Electrostatic stabilization "may be destroyed due to the influence of electrolytes in gastrointestinal fluids" (Li et al. 2021). Dissolved curcumin is then exposed to the same pH-dependent degradation as any other form.
- Physical stability
- Small particles have high surface energy, which drives aggregation, sedimentation and Ostwald ripening; redispersibility after drying is a key factor for solid products (Li et al. 2021).
Typical failure modes: particle growth in storage; aggregation in gut fluid; incomplete redispersion of a dried powder; a gain in rate that the dose number makes irrelevant.
Confirmatory experiments: particle size by laser diffraction and dynamic light scattering over storage; X-ray powder diffraction and calorimetry to confirm the crystal form is kept; size and charge in biorelevant media; non-sink dissolution; then a human PK study.
Curcumin evidence: rats, 16-fold for a nanocrystal solid dispersion (Onoue et al. 2010); human PK for a colloidal nanoparticle preparation of unstated crystallinity, 27-fold (Sasaki et al. 2011). Details
Amorphous solid dispersion: remove the crystal lattice to create supersaturation
What it changes: the energy of the solid. Curcumin is dispersed in a polymer glass without a crystal lattice, so dissolution can produce concentrations above the crystalline solubility. Supersaturating systems must then "be stabilized to allow for significant absorption", for example with precipitation inhibitors (Brouwers et al. 2009). The gain is kinetic and lasts only until the drug crystallizes.
- Loading and excipient burden
- Limited by how much drug the polymer holds in one phase, which depends on drug, polymer and process (Bhujbal et al. 2021). At a hypothetical 20% drug loading, 500 mg of curcumin would come in 2.5 g of dispersion.
- Dilution and the gut
- The supersaturated solution can precipitate after dissolution; whether the polymer holds it depends on the polymer, the dose and the medium (Brouwers et al. 2009).
- Physical stability
- Moisture lowers the glass transition temperature and raises the risk of crystallization; amorphous–amorphous phase separation can also undo the advantage (Bhujbal et al. 2021). For curcumin, polymers inhibited crystallization, but most were "not highly effective" in long-term storage, which the authors linked to curcumin's intramolecular hydrogen bonding (Wegiel et al. 2014).
Typical failure modes: recrystallization in storage, especially in humidity; phase separation; precipitation in the gut after supersaturation; degradation of the dissolved drug.
Confirmatory experiments: X-ray powder diffraction and calorimetry (crystallinity, glass transition) under accelerated temperature and humidity; infrared evidence of drug–polymer interaction; non-sink, two-stage (gastric to intestinal pH) dissolution with supersaturation and precipitation followed over time; stability-indicating HPLC; then a human PK study.
Curcumin evidence: in vitro storage stability (Wegiel et al. 2014) and rats, 12-fold (Onoue et al. 2010); a human study is listed in a systematic review, but its report was not reviewed. Details
Pouton CW. Eur J Pharm Sci. 2006;29:278–287; Williams HD, et al. Pharm Res. 2013;30(12):3059–3076; Cui J, et al. Int J Pharm. 2009;371:148–155; Saokham P, et al. Molecules. 2018;23(5):1161; Păduraru DN, et al. Pharmaceutics. 2022;14(8):1748; Tønnesen HH, et al. Int J Pharm. 2002;244:127–135 (abstract); Müller RH, et al. Eur J Pharm Biopharm. 2011;78:1–9; Li J, et al. Drug Deliv. 2021;28(1):19–36; Brouwers J, et al. J Pharm Sci. 2009;98(8):2549–2572; Bhujbal SV, et al. Acta Pharm Sin B. 2021;11(8):2505–2536; Wegiel LA, et al. Pharm Dev Technol. 2014;19(8):976–986; Kharat M, et al. 2017.
04 · Side by side
The quantity a strategy changes decides which test can show it worked
| Strategy | Changes | Main constraint for curcumin | Typical failure | Deciding laboratory test |
|---|---|---|---|---|
| Lipid-based SNEDDS | Solubilized state (no dissolution step) | Capacity: about 24 g of preconcentrate for 500 mg at 21 mg/g | Precipitation on dilution or digestion | In vitro lipolysis with phase separation and solid-form check |
| Cyclodextrin complex | Apparent solubility (equilibrium) | Mass: at least 3.1–3.5 g of cyclodextrin per g | Low complexation efficiency; bulk | Phase-solubility diagram and dilution test |
| Nanocrystal | Dissolution rate (surface area) | Dose number stays far above 1 | Particle growth, aggregation | Non-sink dissolution; size and form over storage |
| Amorphous solid dispersion | Supersaturation (kinetic) | Physical stability: crystallization inhibition was limited | Recrystallization; precipitation in the gut | Two-stage supersaturation test; humidity stability |
None of the four addresses metabolism or elimination, and all four leave dissolved curcumin exposed at intestinal pH. These are reasons to measure degradation products alongside dissolved curcumin in every test.
05 · Published evidence for curcumin
Human exposure data exist for some strategies and are missing or not yet reviewed for others
Each cell names the cited study and what it measured. Fold-changes from different studies are not comparable: they differ in comparator, dose, analyte (free curcumin or total curcuminoids after hydrolysis) and species.
| Strategy | In vitro | Animal | Human pharmacokinetics |
|---|---|---|---|
| Lipid-based (self-microemulsifying) | Droplets about 21 nm on dilution; more than 95% dissolved in 20 min at pH 1.2 or 6.8, against less than 2% of crude curcumin in 60 min (Cui et al. 2009) | Absorption by passive diffusion in rat intestine in situ; significantly higher oral absorption than a suspension in mice (Cui et al. 2009) | No self-emulsifying study found. A systematic review lists a microemulsion among five systems tested in healthy volunteers (Pan-On et al. 2022); its report was not reviewed. A liquid micellar formulation, a different system, gave 185-fold higher total curcuminoid AUC (Schiborr et al. 2014) |
| Cyclodextrin | Water solubility at pH 5 raised at least 104-fold; alkaline hydrolytic stability improved; photodecomposition faster (Tønnesen et al. 2002) | None found | γ-Cyclodextrin formulation: 39-fold higher total curcuminoid AUC0–12 h than unformulated extract; 12 volunteers, double-blind crossover (Purpura et al. 2018) |
| Nanocrystal or particle-size reduction | Marked improvement in dissolution against crystalline curcumin; high photochemical stability as a solid (Onoue et al. 2010) | Nanocrystal solid dispersion: 16-fold higher oral bioavailability in rats (Onoue et al. 2010) | Colloidal nanoparticle preparation: 27-fold higher AUC at 30 mg (Sasaki et al. 2011; the abstract does not state whether the particles are crystalline). Micronized powder: 9-fold (Schiborr et al. 2014) |
| Amorphous solid dispersion | Polymers inhibited crystallization, with limited long-term effect (Wegiel et al. 2014) | 12-fold higher oral bioavailability in rats (Onoue et al. 2010) | A systematic review lists a solid dispersion among five systems tested in healthy volunteers (Pan-On et al. 2022); that study's report was not reviewed, so no number is quoted |
The one study that compared three of the strategies side by side, in rats, ranked the nanocrystal solid dispersion (16-fold), the amorphous dispersion (12-fold) and a nanoemulsion (9-fold) against crystalline curcumin (Onoue et al. 2010). A rank order in one animal study is a hypothesis for a human study, not a result for a product.
Why fold-changes are hard to compare
Many curcumin studies treated plasma with glucuronidase and sulfatase before analysis, so they report conjugated metabolites together with free curcumin; Stohs and colleagues call this "widely used but inappropriate". Comparators differ (crystalline powder, standardized extract), doses differ and must be normalized on an assumption of proportionality, and sex alone changed one micellar result from 114-fold in men to 277-fold in women (Schiborr et al. 2014). A worked comparison is on Bioavailability by design.
Cui J, et al. 2009; Tønnesen HH, et al. 2002; Purpura M, et al. Eur J Nutr. 2018;57(3):929–938; Onoue S, et al. J Pharm Sci. 2010;99(4):1871–1881 (Sprague-Dawley rats); Sasaki H, et al. Biol Pharm Bull. 2011;34(5):660–665; Schiborr C, et al. Mol Nutr Food Res. 2014;58(3):516–527; Wegiel LA, et al. 2014; Pan-On S, et al. J Control Release. 2022;348:335–345; Stohs SJ, et al. Molecules. 2020;25(6):1397.
06 · How EUTECNIQ proposes to decide
Four checkpoints, each with a stop rule written before the work starts
EUTECNIQ would choose between strategies with preset acceptance limits and would stop a candidate at the first checkpoint it fails. Human studies would be run by qualified clinical partners under ethics approval. Proposed capability
- 1
Screen
Verify the molecule's properties and compute Do and Dn. Map stability against pH and check each candidate excipient's status for the intended product category. Fix the dose and format.
Stop if no lawful excipient set can carry the dose in an acceptable serving.
- 2
Prototype
Build two to four candidates, only from families that act on the diagnosed limit; confirm loading, solid form and assay for each.
Stop if loading falls short of what the dose needs, or the intended form (complex, amorphous, crystalline) is not confirmed.
- 3
Dispersion and digestion tests
Run a dilution series, two-stage non-sink dissolution, and in vitro lipolysis for lipid systems or static digestion (INFOGEST, which its authors state is "not suitable for simulating digestion kinetics"). Measure dissolved curcumin, precipitate form and degradation products together, and test storage stability.
Stop if precipitation, degradation or physical change exceeds the preset limits.
- 4
PK plan with a partner
A crossover design against a dose-matched unformulated comparator, with free curcumin and its conjugates measured separately by a validated method and the sample size justified in advance.
Result: exposure for that formulation against that comparator. Benefit needs an outcome study.
- Higher apparent solubility does not by itself mean higher absorption.
- Small droplets or particles do not by themselves show higher systemic exposure.
- Bioaccessibility in vitro is not systemic bioavailability.
- Higher plasma curcuminoids do not show benefit.
- One product's PK study is not evidence for another product.
Brodkorb A, et al. Nat Protoc. 2019;14:991–1014; Stohs SJ, et al. 2020. Gate structure: EUTECNIQ proposal; see the platform plan and Advanced delivery.
Working on an ingredient that will not dissolve?
Share the molecule's known properties, the intended dose and the product category. EUTECNIQ is in formation and would respond with a proposed screen and the evidence each gate would produce.
07 · Sources
Sources cited in this demonstration
Reviewed November 1, 2026: full text where noted, otherwise the PubMed abstract. All entries also appear on the Sources page.
Show the 30 sources
- PubChem Compound Summary, Curcumin (CID 969516): molecular weight and XLogP3 (computed); melting point from HSDB and EU Food Improvement Agents; "Insoluble in water" (HSDB). pubchem.ncbi.nlm.nih.gov/compound/969516
- Priyadarsini KI. The chemistry of curcumin: from extraction to therapeutic agent. Molecules. 2014;19(12):20091–20112 (full text). doi:10.3390/molecules191220091
- Nelson KM, Dahlin JL, Bisson J, Graham J, Pauli GF, Walters MA. The essential medicinal chemistry of curcumin. J Med Chem. 2017;60(5):1620–1637 (full text). doi:10.1021/acs.jmedchem.6b00975
- Brotons-Canto A, González-Navarro CJ, Gil AG, et al. Zein nanoparticles improve the oral bioavailability of curcumin in Wistar rats. Pharmaceutics. 2021;13(3):361 (full text; quotes 11 ng/mL at pH 5). doi:10.3390/pharmaceutics13030361
- Bernabé-Pineda M, Ramírez-Silva MT, Romero-Romo M, González-Vergara E, Rojas-Hernández A. Determination of acidity constants of curcumin in aqueous solution and apparent rate constant of its decomposition. Spectrochim Acta A Mol Biomol Spectrosc. 2004;60(5):1091–1097. doi:10.1016/S1386-1425(03)00342-1
- Wang YJ, Pan MH, Cheng AL, et al. Stability of curcumin in buffer solutions and characterization of its degradation products. J Pharm Biomed Anal. 1997;15(12):1867–1876. doi:10.1016/s0731-7085(96)02024-9
- Kharat M, Du Z, Zhang G, McClements DJ. Physical and chemical stability of curcumin in aqueous solutions and emulsions: impact of pH, temperature, and molecular environment. J Agric Food Chem. 2017;65(8):1525–1532. doi:10.1021/acs.jafc.6b04815
- Anand P, Kunnumakkara AB, Newman RA, Aggarwal BB. Bioavailability of curcumin: problems and promises. Mol Pharm. 2007;4(6):807–818. doi:10.1021/mp700113r
- Tønnesen HH, Másson M, Loftsson T. Studies of curcumin and curcuminoids. XXVII. Cyclodextrin complexation: solubility, chemical and photochemical stability. Int J Pharm. 2002;244(1–2):127–135 (abstract only). doi:10.1016/s0378-5173(02)00323-x
- Amidon GL, Lennernäs H, Shah VP, Crison JR. A theoretical basis for a biopharmaceutic drug classification. Pharm Res. 1995;12(3):413–420. doi:10.1023/A:1016212804288
- Abuhassan Q, Khadra I, Pyper K, Augustijns P, Brouwers J, Halbert GW. Fasted intestinal solubility limits and distributions applied to the biopharmaceutics and developability classification systems. Eur J Pharm Biopharm. 2022;170:160–169. doi:10.1016/j.ejpb.2021.12.006
- ICH M9. Biopharmaceutics Classification System-Based Biowaivers. Adopted November 20, 2019. database.ich.org
- Dokoumetzidis A, Macheras P. A century of dissolution research: from Noyes and Whitney to the biopharmaceutics classification system. Int J Pharm. 2006;321(1–2):1–11. doi:10.1016/j.ijpharm.2006.07.011
- Pouton CW. Formulation of poorly water-soluble drugs for oral administration: physicochemical and physiological issues and the lipid formulation classification system. Eur J Pharm Sci. 2006;29(3–4):278–287. doi:10.1016/j.ejps.2006.04.016
- Williams HD, Sassene P, Kleberg K, et al. Toward the establishment of standardized in vitro tests for lipid-based formulations, part 3. Pharm Res. 2013;30(12):3059–3076. doi:10.1007/s11095-013-1038-z
- Cui J, Yu B, Zhao Y, et al. Enhancement of oral absorption of curcumin by self-microemulsifying drug delivery systems. Int J Pharm. 2009;371(1–2):148–155. doi:10.1016/j.ijpharm.2008.12.009
- Saokham P, Muankaew C, Jansook P, Loftsson T. Solubility of cyclodextrins and drug/cyclodextrin complexes. Molecules. 2018;23(5):1161 (full text). doi:10.3390/molecules23051161
- Păduraru DN, Niculescu AG, Bolocan A, et al. An updated overview of cyclodextrin-based drug delivery systems for cancer therapy. Pharmaceutics. 2022;14(8):1748 (Table 1). doi:10.3390/pharmaceutics14081748
- Purpura M, Lowery RP, Wilson JM, et al. Analysis of different innovative formulations of curcumin for improved relative oral bioavailability in human subjects. Eur J Nutr. 2018;57(3):929–938. doi:10.1007/s00394-016-1376-9
- Müller RH, Gohla S, Keck CM. State of the art of nanocrystals. Eur J Pharm Biopharm. 2011;78(1):1–9. doi:10.1016/j.ejpb.2011.01.007
- Li J, Wang Z, Zhang H, Gao J, Zheng A. Progress in the development of stabilization strategies for nanocrystal preparations. Drug Deliv. 2021;28(1):19–36 (full text). doi:10.1080/10717544.2020.1856224
- Onoue S, Takahashi H, Kawabata Y, et al. Formulation design and photochemical studies on nanocrystal solid dispersion of curcumin with improved oral bioavailability. J Pharm Sci. 2010;99(4):1871–1881. doi:10.1002/jps.21964
- Sasaki H, Sunagawa Y, Takahashi K, et al. Innovative preparation of curcumin for improved oral bioavailability. Biol Pharm Bull. 2011;34(5):660–665. doi:10.1248/bpb.34.660
- Schiborr C, Kocher A, Behnam D, Jandasek J, Toelstede S, Frank J. The oral bioavailability of curcumin from micronized powder and liquid micelles is significantly increased in healthy humans and differs between sexes. Mol Nutr Food Res. 2014;58(3):516–527. doi:10.1002/mnfr.201300724
- Brouwers J, Brewster ME, Augustijns P. Supersaturating drug delivery systems: the answer to solubility-limited oral bioavailability? J Pharm Sci. 2009;98(8):2549–2572. doi:10.1002/jps.21650
- Bhujbal SV, Mitra B, Jain U, et al. Pharmaceutical amorphous solid dispersion: a review of manufacturing strategies. Acta Pharm Sin B. 2021;11(8):2505–2536 (full text). doi:10.1016/j.apsb.2021.05.014
- Wegiel LA, Zhao Y, Mauer LJ, Edgar KJ, Taylor LS. Curcumin amorphous solid dispersions: the influence of intra and intermolecular bonding on physical stability. Pharm Dev Technol. 2014;19(8):976–986. doi:10.3109/10837450.2013.846374
- Pan-On S, Dilokthornsakul P, Tiyaboonchai W. Trends in advanced oral drug delivery system for curcumin: a systematic review. J Control Release. 2022;348:335–345. doi:10.1016/j.jconrel.2022.05.048
- Stohs SJ, Chen O, Ray SD, Ji J, Bucci LR, Preuss HG. Highly bioavailable forms of curcumin and promising avenues for curcumin-based research and application: a review. Molecules. 2020;25(6):1397. doi:10.3390/molecules25061397
- Brodkorb A, Egger L, Alminger M, et al. INFOGEST static in vitro simulation of gastrointestinal food digestion. Nat Protoc. 2019;14:991–1014. doi:10.1038/s41596-018-0119-1
Health information notice. These statements have not been evaluated by the Food and Drug Administration. Nothing on this site is intended to diagnose, treat, cure or prevent any disease, and nothing here is medical advice.
Read the full notice
The information is for general education only. It does not replace advice, diagnosis or treatment from a qualified health professional, or any medication a clinician has prescribed. Do not start, stop or change any medicine, supplement or herbal product because of something you read here. Talk to your doctor or pharmacist first, especially if you are pregnant or breastfeeding, have a medical condition, take any medicines, are preparing for surgery, or are caring for a child. Research findings, traditional uses and safety data are reported as their sources state them; they are not recommendations or claims about any product. If you think you may have a medical emergency, call your doctor or 911 at once.
EUTECNIQ Sciences sells no supplements or health products today and receives nothing from any product or ingredient mentioned on this site; any commercial interest it later has in an ingredient will be stated on that ingredient’s page.